Eledon Pharmaceuticals, Inc.
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2016
- $0
- Net income
- -$45.6M
- Total assets
- $169.0M
- Market cap
- $263.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating expenses
- $83.3M
- Income tax
- $35.0K
- Net income
- -$45.6M
- EPS (basic)
- $-0.52
- EPS (diluted)
- $-0.52
Balance sheet
- Total assets
- $169.0M
- Current assets
- $135.7M
- Total liabilities
- $32.2M
- Current liabilities
- $18.3M
- Shareholders’ equity
- $81.1M
Cash flow
- Operating cash flow
- -$62.3M
- Investing cash flow
- $10.8M
- Financing cash flow
- $53.8M
- Net cash flow
- $2.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $263.2M
- EPS (diluted)
- $-0.52
- Shares outstanding
- 73.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 17, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $45.6M in FY2016.
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Eledon Pharmaceuticals, Inc..
Write a review
News about Eledon Pharmaceuticals, Inc.
News & sentiment via Polygon.io
